ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis has agreed to sell its Xiidra treatment for dry eye disease and other ophthalmology assets to Bausch + Lomb for $1.75 billion plus milestone payments that could bring the deal to $2.5 billion. The deal also includes SAF312, a therapy in development for treatment of chronic ocular surface pain, and a TRPV1 antagonist. Bausch + Lomb will also assume rights for use of the AcuStream delivery device in dry eye indications.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter